Analytical Data
-
Gene name
Kallikrein-6
- Application
-
Alternative Names
ZYME; Bssp; Klk7; Neurosin,Zyme; PRSS18; PRSS9; SP59; HK6; Protease M; Serine protease 18
-
Species
Mouse
-
Source
E. coli
-
Tag
Two N- s, His- & SUMO-
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q91Y82
-
Expression Region
Glu24~Leu253
-
Molecular Weight
44kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Kallikrein-6 (KLK6) is a member of the kallikrein-related peptidase family, which is known to play crucial roles in various physiological processes, including tissue homeostasis, inflammation, and neurodegeneration. Research has indicated that KLK6 is overexpressed in several types of cancers, especially in ovarian and prostate cancers, making it a potential biomarker for early detection and a target for therapeutic intervention. The enzyme is also involved in neurodegenerative diseases such as Alzheimer's, where it may affect amyloid precursor protein processing and tau phosphorylation, contributing to the pathogenesis of these conditions. Its multifunctional properties, including proteolytic activity, have spurred interest in developing KLK6 as a therapeutic target and diagnostic tool. Recombinant KLK6 proteins have been produced to facilitate studies on its biological functions, mechanisms of action, and interactions with other molecules. Understanding KLK6's role in disease processes could lead to novel approaches in diagnosis and treatment. As such, the study of KLK6 recombinant proteins is gaining momentum, aiming to unlock the therapeutic potential and clarify the enzyme's involvement in various pathological conditions.
